Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novo Integrated Sciences has a Cash Ratio of 0.07. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Novo Integrated Sciences's Cash Ratio or its related term are showing as below:
NVOS's Cash Ratio is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 0.59 * Ranked among companies with meaningful Cash Ratio only.
Novo Integrated Sciences (OTCPK:NVOS) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Novo Integrated Sciences Cash Ratio Related Terms
Novo Integrated Sciences Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Novo Integrated Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Integrated Sciences Cash Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Novo Integrated Sciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Integrated Sciences (NVOS) has a Cash Ratio of 0.07 as of May. 2024. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Novo Integrated Sciences and its competitors.
Is Novo Integrated Sciences' Cash Ratio too high?
Novo Integrated Sciences' current Cash Ratio is 0.07. The Healthcare Providers & Services industry median Cash Ratio is 0.59. Novo Integrated Sciences' value of 0.07 is 88.1% below this industry median. Overall, Novo Integrated Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Novo Integrated Sciences' Cash Ratio compare to BACK and NHLG?
Novo Integrated Sciences' Cash Ratio of 0.07 can be compared against companies in the Healthcare Providers & Services industry. The industry median Cash Ratio is 0.59. Novo Integrated Sciences' value of 0.07 is 88.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Healthcare Providers & Services company?
The median Cash Ratio among Healthcare Providers & Services companies is 0.59, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novo Integrated Sciences's current Cash Ratio of 0.07 is 88.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Novo Integrated Sciences and its competitors. For the Healthcare Providers & Services industry, the median Cash Ratio is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Integrated Sciences's current Cash Ratio is 0.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Integrated Sciences stock overvalued right now?
Novo Integrated Sciences (NVOS) has a current Cash Ratio of 0.07. The current Cash Ratio is 0.07 and 88.1% below the Healthcare Providers & Services industry median of 0.59. Novo Integrated Sciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Novo Integrated Sciences (NVOS), the current Cash Ratio is 0.07 as of May. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services and product sales. Healthcare services generate the majority of revenue.
12GF Score
Get the complete analysis for NVOS
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVOS has been successfully added to your 
